Volk, H A and Matiasek, L A and Feliu-Pascual, A L and Platt, S R and Chandler, K E (2008) The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. VETERINARY JOURNAL, 176 (3). pp. 310-319.
![[img]](https://researchonline.rvc.ac.uk/style/images/fileicons/text.png) |
Text
1732.pdf Restricted to Repository staff only Download (189kB) |
Abstract
Twenty-two dogs with idiopathic epilepsy which were pharmacoresistant to phenobarbitone and bromide were treated with levetiracetam as an add-on medication. Records of eight dogs were used retrospectively to determine a safe, efficient levetiracetam dosage. Fourteen dogs were entered into a prospective, open label, non-comparative study. After 2 months of levetiracetam oral treatment (10 mg/kg TID), 8/14 dogs responded significantly to the treatment and seizure frequency was reduced by >= 50%. In dogs that remained refractory, the dosage was increased to 20 mg/kg TID for 2 months. One further dog responded to levetiracetam treatment. Levetiracetam, responders had a significant decrease in seizure frequency of 77% (7.9 +/- 5.2 to 1.8 +/- 1.7 seizures/month) and a decrease in seizure days per month of 68% (3.8 +/- 1.7 to 1.2 +/- 1.1 seizure days/month). However, 6/9 responders experienced an increase in seizure frequency and seizure days after 4-8 months continuing with the levetiracetam treatment at the last effective dosage. Levetiracetam was well tolerated by all dogs and sedation was the only side-effect reported in just one of the 14 dogs. (c) 2007 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| RVC Publication Type: | Research (full) paper |
| WoS ID: | 000256335100007 |
| DOI: | https://doi.org/10.1016/j.tvjl.2007.03.002 |
| Departments: | Clinical Sciences and Services |
| Research Programmes: | Comparative Physiology & Medicine > Clinical Research |
| Depositing User: | RVC Auto-import |
| Last Modified: | 21 Feb 2020 12:51 |
| URI: | http://researchonline.rvc.ac.uk/id/eprint/1732 |